Nanoparticle Distributed Intravenous Enzyme Replacement Therapy (NanoDIVERT)
纳米颗粒分布式静脉酶替代疗法(NanoDIVERT)
基本信息
- 批准号:10723846
- 负责人:
- 金额:$ 40.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAffectAgeAnimal ModelAnimalsApolipoprotein EApolipoproteinsAreaAutopsyBiodistributionBloodBlood - brain barrier anatomyBrainBrain DiseasesCOVID-19 vaccineCellsCentral Nervous SystemClinicClinicalClinical TrialsDataDevelopmentDiseaseDoseDyesEncapsulatedEnzymesFamilyFamily FelidaeForelimbFutureGLB1 geneGangliosidosis GM1Genetic DiseasesGoalsHalf-LifeHourHumanInflammationInjectionsIntravenousIntravenous infusion proceduresLaboratoriesLow-Density LipoproteinsLysosomal Storage DiseasesLysosomesMarketingMediatingModelingMonitorMusNeurologicNeuropathyOrphanOutcome StudyPatientsPerformanceProductionProteinsRecombinantsRegimenSeverity of illnessSpecificitySpinal CordSurfaceSymptomsSystemTestingTherapeuticTherapeutic EffectTimeTissuesTreatment EfficacyVariantVesicleadeno-associated viral vectorappropriate dosebeta-Galactosidaseclinically relevantcommon symptomenzyme activityenzyme replacement therapyflexibilitygene therapyimprovedin vivoin vivo imaging systeminfancyintravenous injectionmortalitymouse modelnanoparticlenear infrared dyeneuralneurotoxicitypreventreceptorreduce symptomsscale upsuccessvector
项目摘要
PROJECT ABSTRACT
Enzyme replacement therapy (ERT) has been successful in ameliorating symptoms of patients with non-
neuropathic lysosomal storage disorders (LSDs), making it a viable therapeutic approach for these rare, orphan
genetic diseases. Essentially, patients receive intravenous (IV) infusions of endogenous enzymes that are either
present at low concentration, missing entirely, or misfolded, and therefore dysfunctional due to their genetic
disease. Despite its promise in the clinic, ERT cannot be used to treat 50-70% of LSDs with central nervous
system manifestation due to the blood-brain barrier (BBB) which prevents the passage of recombinant enzymes
from the blood into the brain. One of these diseases and the focus of this proposal, GM1 gangliosidosis, arises
from variants in GLB1 that leads to decreased production of lysosomal β-galactosidase (βgal). Its most common
form results in mortality between the ages of 2 and 4. Recently, our laboratory has created nanoparticle vesicles,
called polymersomes, capable of encapsulating and delivering βgal to lysosomes of GM1-affected cells, where
the delivered enzyme maintains its activity. Preliminary data in a feline model of GM1 gangliosidosis shows that
with the addition of an apolipoprotein on the surface, polymersomes transport active βgal across the BBB within
48 hours after an intravenous forelimb injection. This approach to treatment, titled nanoparticle distributed IV
ERT (NanoDIVERT), can potentially extend ERT into the central nervous system, which could impact not only
GM1 gangliosidosis but also other orphan neuropathic LSDs. To further test the applicability of the nanoparticle-
mediated approach to IV ERT, we will optimize in vivo performance. Specifically, we aim to increase delivery to
the brain and determine the most appropriate dosing for therapeutic effects. We aim to initially optimize
NanoDIVERT in a murine model of GM1 gangliosidosis, for testing in greater animal numbers, before scaling up
to large animal models. The outcome of these studies could enable the development of a clinically relevant ERT
for GM1 gangliosidosis and other neuropathic LSDs for the first time.
项目摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jessica Marie Larsen其他文献
Jessica Marie Larsen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 40.46万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 40.46万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 40.46万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 40.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 40.46万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 40.46万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 40.46万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 40.46万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 40.46万 - 项目类别:
Miscellaneous Programs